Evidence map›Paper›PMID 27137185›Full record

ArticleCellular and molecular life sciences : CMLS2016

Unique patterns of CD8+ T-cell-mediated organ damage in the Act-mOVA/OT-I model of acute graft-versus-host disease.

Barbara Érsek, Nikolett Lupsa, Péter Pócza, Anett Tóth, Andor Horváth, Viktor Molnár, Bence Bagita, András Bencsik, Hargita Hegyesi, András Matolcsy and 2 more

Open access · greenAbstract read
In one paragraph

Article in Cellular and molecular life sciences : CMLS, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
–field-weighted citation impact, top 97% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed, 4 citations in OpenAlex.

  1. Article
  2. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

12 authors at 2 institutions in 2 countries.

Barbara ÉrsekHungarian Academy of Sciences-Semmelweis University, "Lendület" Experimental and Translational Immunomics Research Group, 1089, Budapest, Hungary.
Nikolett LupsaHungarian Academy of Sciences-Semmelweis University, "Lendület" Experimental and Translational Immunomics Research Group, 1089, Budapest, Hungary.
Péter Pócza1st Department of Pathology and Experimental Cancer Research, Semmelweis University, 1085, Budapest, Hungary.
Anett TóthHungarian Academy of Sciences-Semmelweis University, "Lendület" Experimental and Translational Immunomics Research Group, 1089, Budapest, Hungary.
Andor HorváthHungarian Academy of Sciences-Semmelweis University, "Lendület" Experimental and Translational Immunomics Research Group, 1089, Budapest, Hungary.
Viktor MolnárDepartment of Genetics, Cell and Immunobiology, Semmelweis University, 1089, Budapest, Hungary.
Bence BagitaHungarian Academy of Sciences-Semmelweis University, "Lendület" Experimental and Translational Immunomics Research Group, 1089, Budapest, Hungary.
András BencsikHungarian Academy of Sciences-Semmelweis University, "Lendület" Experimental and Translational Immunomics Research Group, 1089, Budapest, Hungary.
Hargita Hegyesi"Frédéric Joliot-Curie" Institute for Radiobiology and Radiohygiene, 1221, Budapest, Hungary.
András Matolcsy1st Department of Pathology and Experimental Cancer Research, Semmelweis University, 1085, Budapest, Hungary.
Edit I BuzásDepartment of Genetics, Cell and Immunobiology, Semmelweis University, 1089, Budapest, Hungary.
Zoltán PósHungarian Academy of Sciences-Semmelweis University, "Lendület" Experimental and Translational Immunomics Research Group, 1089, Budapest, Hungary. pos.zoltan@med.semmelweis-univ.hu.ORCID 0000-0002-2574-7616
Semmelweis University · HUFrédéric Joliot-Curie National Research Institute for Radiobiology and Radiohygiene · HU

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

T-cell receptor (TCR)-transgenic models of acute graft-versus-host disease (aGvHD) offer a straightforward and highly controlled approach to study the mechanisms and consequences of T-cell activation following allogeneic hematopoietic stem cell transplantation (aHSCT). Here, we report that aHSCT involving OT-I mice as donors, carrying an ovalbumin-specific CD8+ TCR, and Act-mOVA mice as recipients, expressing membrane-bound ovalbumin driven by the β-actin promoter, induces lethal aGvHD in a CD8+ T-cell-dependent, highly reproducible manner, within 4-7 days. Tracking of UBC-GFP/OT-I graft CD8+ T cells disclosed heavy infiltration of the gastrointestinal tract, liver, and lungs at the onset of the disease, and histology confirmed hallmark features of gastrointestinal aGVHD, hepatic aGvHD, and aGvHD-associated lymphocytic bronchitis in infiltrated organs. However, T-cell infiltration was virtually absent in the skin, a key target organ of human aGvHD, and histology confirmed the absence of cutaneous aGVHD, as well. We show that the model allows studying CD8+ T-cell responses in situ, as selective recovery of graft CD45.1/OT-I CD8+ T cells from target organs is simple and feasible by automated tissue dissociation and subsequent cell sorting. Assessment of interferon-gamma production by flow cytometry, granzyme-B release by ELISA, TREC assay, and whole-genome gene expression profiling confirmed that isolated graft CD8+ T cells remained intact, underwent clonal expansion, and exerted effector functions in all affected tissues. Taken together, these data demonstrate that the OT-I/Act-mOVA model is suitable to study the CD8+ T-cell-mediated effector mechanisms in a disease closely resembling fatal human gastrointestinal and hepatic aGVHD that may develop after aHSCT using HLA-matched unrelated donors.

Indexed as

Organ SpecificityActinsAcute DiseaseAnimalsCD8-Positive T-LymphocytesCell MembraneCell ProliferationCell TrackingChickensClone CellsDisease Models, AnimalFlow CytometryGene Expression ProfilingGraft vs Host DiseaseMice, Inbred C57BLMice, TransgenicActinsOvalbuminCAG-OVACytotoxic T cellExperimental modelHoming

Identifiers

PMID27137185
PMCPMC11108436
OpenAlexW2344417270

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.